CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists. In preclinical studies, CR665 was highly selective for the peripheral kappa opioid... Preclinical animal studies suggest that CR665 is a potent analgesic compound.
- Mechanism
- Curator reviewed
CR665 was highly selective for the peripheral kappa opioid receptor. It is intrinsically poor at penetrating the blood-brain barrier, which decreases the likelihood of CNS-mediated side effects. By acting with unprecedented selectivity at pain relieving receptors on peripheral nerves, and avoiding receptors in the central nervous system and gastrointestinal tract, CR665 has the potential to provide pain relief with minimal side effects.
- Primary indication
- Investigated for use/treatment in pain (acute or chronic).Curator reviewed
- Formula / weight
- C36H49N9O4 · 671.847 g/mol (avg)
- Code names
- CR 665 · FE-200665
Resolves to
DBOGGOVKHSCMNB-OMRVPHBLSA-NSMILESCCCC[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC1=CC=NC=C1What you can answer from here — as of March 06, 2025
Which drugs share a target with CR665, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account